Teva Pharmaceutical Industries Limited · TASE:TEVA

Teva Pharmaceutical Industries — FY2010 Earnings Presentation

10 slides from Teva Pharmaceutical Industries's earnings presentation, Feb 9, 2011

  1. Slide 1: Full Year 2010 Earnings

    Full Year 2010 Earnings Shlomo Yanai, President & CEO Investor Relations February 9, 2011 Investor Relations 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements TODAY’S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE OUR FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIF

  3. Slide 3: 2010 – Record Results

    2010 – Record Results 2009* 2010* Change Sales 13,899 16,121 +16% $m Operating income 3,853 4,933 +28% $m Net income 3,029 4,134 +36% $m EPS 3.37 4.54 +35% $ Cash 3,373 4,136 +23% $m *Net income, operating income and EPS are non-GAAP results Investor Relations 3

  4. Slide 4: 2010 Highlights – On Track Towards our Strategic Goals

    2010 Highlights – On Track Towards our Strategic Goals  Exclusive launches drive US generics sales to $5.8 billion (up 16%)  Teva becomes #1 player in Europe with the acquisition of ratiopharm  After 5 months – one face to the market  Russia, Japan and Latin America lead the way in emerging gene

  5. Slide 5: Targets for 2015

    Targets for 2015 Revenues $31B Net income $6.8B Net profitability 22% Investor Relations 5

  6. Slide 6: 2015 Sales – Right On Track Towards Our Strategic Goals

    2015 Sales – Right On Track Towards Our Strategic Goals $31B CAGR = 14% $18.5-19B $16.1B $13.9B US$ Billion 2009A 2010A 2011E 2015E Investor Relations 6

  7. Slide 7: 2015 EPS – Right On Track Towards Our Strategic Goals

    2015 EPS – Right On Track Towards Our Strategic Goals $7.16 CAGR = 13.5% $4.9-5.2 $4.54 $3.37 US$ 2009A 2010A 2011E 2015E Investor Relations 7

  8. Slide 8: Priorities for 2011 and Beyond

    Priorities for 2011 and Beyond  Quality is our first priority  Expand and deepen our presence in Emerging Generics Markets  Leverage our scale as a #1 leader in the US and Europe  Further strengthen and diversify branded portfolio and pipeline Teva is well positioned to achieve its long-term tar

  9. Slide 9: Thank you!

    Thank you! Investor Relations 9

  10. Slide 10: Strong M&A Track Record

    Strong M&A Track Record CAGR of 22% CAGR of 31% Index 1995=100 CoGenesys Theramex income Europe / WH Sales US / biopharma Net Bentley ratiopharm Spain Europe Barr Infarmassa 6,000 Pharmachemie Sicor Global Peru Netherlands Global Medilac (50%) 5,000 JK Turkey APS / Berk India / API Ivax UK Global 4,

Teva Pharmaceutical Industries — FY2010 Earnings Presentation on 6ix